<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810381</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-211097</org_study_id>
    <nct_id>NCT00810381</nct_id>
  </id_info>
  <brief_title>Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects</brief_title>
  <official_title>Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma, one of the most common causes of blindness, is associated with increased
      intraocular pressure (IOP) and optic nerve head ischemia. Nitrovasodilators are discussed in
      the treatment of glaucoma. Nitrates relax smooth muscle cells in the vasculature by
      liberating the vasodilator nitric oxide.

      The IOP lowering potential and the vasodilator action in retinal and choroidal vessels of
      nitrates is still a matter of controversy. Previous studies on the ocular hemodynamic effects
      of nitrates showed partially contradicting results. In addition the IOP lowering effect of
      nitrates is still unclear. However, recent studies show that long acting nitrates may
      preserve optic nerve deterioration and visual field loss.

      Therefore, the role of nitrovasodilators in control of ocular blood flow and intraocular
      pressure has to be elucidated. For this purpose the investigators plan to test the hypothesis
      that nitrovasodilators improve ocular blood supply to the optic nerve head at doses which do
      not affect systemic hemodynamics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">June 1999</completion_date>
  <primary_completion_date type="Actual">June 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic disc blood flow (laser Doppler flowmetry)</measure>
    <time_frame>in total 24x on 4 study days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>in total 8x in 4 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Choroidal blood flow (laser Doppler flowmetry)</measure>
    <time_frame>in total 24x on 4 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus pulsation amplitude in the macula (laser interferometry)</measure>
    <time_frame>in total 24x on 4 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus pulsation amplitude in the optic disc (laser interferometry)</measure>
    <time_frame>in total 24x on 4 study days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure, pulse rate</measure>
    <time_frame>on 4 study days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):
0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):
0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):
0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide-Dinitrate</intervention_name>
    <description>intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium-nitroprusside</intervention_name>
    <description>intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline solution (control substance)</intervention_name>
    <description>intravenous infusion, infusion period 120 minutes</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged between 19 and 35 years, nonsmokers

          -  Body mass index between 15th and 85th percentile (Must et al. 1991)

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal laboratory values unless the investigator considers an abnormality to be
             clinically irrelevant

          -  Normal ophthalmic findings, ametropia &lt; 3 Dpt.

        Exclusion Criteria:

          -  Regular use of medication, abuse of alcoholic beverages, participation in a clinical
             trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  History of hypersensitivity to the trial drug or to drugs with a similar chemical
             structure

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with, distribution, metabolism or excretion of study drugs

          -  History of migraine

          -  Blood donation during the previous 3 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Georg Eichler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hans-Georg Eichler, MD</name_title>
    <organization>Department of Clinical Pharmacology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Nitrovasodilators</keyword>
  <keyword>ONH blood flow</keyword>
  <keyword>Choroidal blood flow</keyword>
  <keyword>Nitroglycerin</keyword>
  <keyword>Isosorbide Dinitrate</keyword>
  <keyword>Sodium nitroprusside</keyword>
  <keyword>Laser-Doppler Flowmetry</keyword>
  <keyword>Regional Blood Flow</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Nitroprusside</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

